Skip to main content

Table 3 Soluble mediator concentrations in sputum supernatants after LPS challenge in each treatment group

From: Inhibition of LPS-induced airway neutrophilic inflammation in healthy volunteers with an oral CXCR2 antagonist

Mediator

N

Arithmetic mean

Geometric mean

P

P#

AZD8309

S.D.

Placebo

S.D.

AZD8309

CV (%)

Placebo

CV (%)

CXCL8 (pg/mL)

16

1373.8

2076.3

2708.2

2880.9

668

251

1404

262

0.1

0.046

CXCL1 (pg/mL)

13

3700.7

5027.0

3934.7

3453.5

2722

75

3622

73

0.044

0.024

LTB4 (ng/mL)

16

0.676

0.530

1.181

0.934

0.54

78

0.87

103

0.075

0.14

NEA (fluor units)

16

3438.8

362.3

6419.4

5793.8

3422

10

5227

66

0.012

0.005

  1. S.D. = standard deviation. P = value by ANOVA; P# = value by Wilcoxon test.
  2. LTB4: leukotriene B4; NEA: neutrophil elastase activity.